.png){kind=icon}
.png){kind=icon}
Return
Dynamic Therapeutic Response to Osimertinib and Immunotherapy in an EGFR L747S and L858R co-mutant NSCLC
.png){kind=icon}
OA
AI
Y
T
J
W
DOI：10.1093/oncolo/oyag227.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are recommended as the first-line standard treatment for advanced lung adenocarcinoma with common EGFR sensitive mutations (exon 19 E746-A750 deletion and exon 21 L858R). However, the optimal management for rare or compound EGFR mutations remains undefined.
Journal
T
IF:
0
Papers:
188
Citations:
0
Organization
Cited Papers